Skip to Content

Cubist Says FDA Approves Fast-Injection Cubicin

From Associated Press (December 1, 2010)


LEXINGTON, Mass. -- Cubist Pharmaceuticals Inc. said Wednesday that regulators gave a new approval to its antibiotic Cubicin, allowing Cubist to market a two-minute injection version of the drug.

The company said the Food and Drug Administration approved marketing of once-daily, two-minute IV injections of Cubicin, which treats complex skin infections like staph injections and the drug-resistant MRSA "superbug." Cubist was originally approved in 2003 as a 30-minute infusion.

"Having to spend only 2 minutes a day receiving CUBICIN, especially for patients in the outpatient setting, minimizes the impact that IV therapy has on their daily activities," Cubist President and CEO Michael W. Bonney said in a statement.

Cubist shares fell 73 cents, or 3.4 percent, to close at $20.98 in Wednesday trading.



Posted: December 2010